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Background: TAFRO syndrome is a unique clinicopathologic variant of multicentric Castleman’s disease that has
recently been identified in Japan. It is characterized by a constellation of symptoms: Thrombocytopenia, Anasarca,
reticulin Fibrosis of the bone marrow, Renal dysfunction and Organomegaly (TAFRO). Previous reports have shown
that affected patients usually respond to immunosuppressive therapy, but the disease sometimes has a fatal course.
TAFRO syndrome occurs in the middle-aged and elderly and there are no prior reports of the disease in adolescents.
Here we report the first adolescent case, successfully treated with anti-IL-6 receptor antibody (tocilizumab, TCZ) and
monitored with serial cytokine profiles.
Case presentation: A 15-year-old Japanese boy was referred to us with fever of unknown origin. Whole body
computed tomography demonstrated systemic lymphadenopathy, organomegaly and anasarca. Laboratory tests
showed elevated C-reactive protein and hypoproteinemia. Bone marrow biopsy revealed a hyperplastic marrow
with megakaryocytic hyperplasia and mild reticulin fibrosis. Despite methylprednisolone pulse therapy, the
disease progressed markedly to respiratory distress, acute renal failure, anemia and thrombocytopenia. Serum
and plasma levels of cytokines, including IL-6, vascular endothelial growth factor, neopterin and soluble tumor
necrosis factor receptors I and II, were markedly elevated. Repeated weekly TCZ administration dramatically
improved the patient’s symptoms and laboratory tests showed decreasing cytokine levels.
Conclusion: To our knowledge, this is the first report of TAFRO syndrome in a young patient, suggesting that
this disease can occur even in adolescence. The patient was successfully treated with TCZ. During our patient’s
clinical course, monitoring cytokine profiles was useful to assess the disease activity of TAFRO syndrome.
Keywords: Thrombocytopenia, Anasarca, reticulin Fibrosis of the bone marrow, Renal dysfunction,
Organomegaly, Tocilizumab, IL-6, VEGF, Neopterin, Soluble TNF-receptorsBackground
TAFRO syndrome is a unique clinicopathologic variant of
multicentric Castleman’s disease that has recently been
identified in Japan [1]. The syndrome is characterized by a
constellation of symptoms: Thrombocytopenia, Anasarca,
reticulin Fibrosis of the bone marrow, Renal dysfunction
and Organomegaly (TAFRO). Although elevated levels of* Correspondence: ikuiku1979@gmail.com
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article, unless otherwise stated.interleukin-6 (IL-6) and vascular endothelial cell growth
factor (VEGF) are seen in the serum and effusions of
patients with TAFRO syndrome, the pathogenesis of
the disease remains obscure [1]. Previous reports [2-6]
have shown that patients respond to immunosuppressive
therapy, but the disease has resulted in a fatal outcome
in some patients [5,6]. This disease occurs in the
middle-aged and elderly [1]; no case of TAFRO syndrome
in adolescence has been reported to date.
Here we report the case of a 15-year-old Japanese boy
with TAFRO syndrome successfully treated with anti-IL-6tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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http://www.biomedcentral.com/1471-2431/14/139receptor antibody (tocilizumab, TCZ) and monitored with
serial precise cytokine profiles. This is the first report of
this disease in an adolescent.
Case presentation
Clinical course
A 15-year-old Japanese boy was referred to us with fever
of unknown origin of 2 weeks’ duration. He had a sys-
tolic murmur and hepatosplenomegaly. The patient’s
superficial lymph nodes were swollen, with a maximum
diameter of 3.0 cm. Laboratory tests showed elevations
in C-reactive protein (CRP; 17.8 mg/dL), soluble IL-2
receptor (2,467 IU/mL), lactate dehydrogenase (511 IU/L)
and D-D dimer (5.6 μg/mL). The patient had decreased
total protein (5.1 g/dL), albumin (1.8 g/dL), immunoglobu-
lin G (729 mg/dL) and cholinesterase (48 IU/L). CompleteA
B
C
Figure 1 Imaging study. The patient had pleural effusion (A) and severe
observed in the mesentery and in the paraaortic lymph nodes at admission
lymphadenopathy, hepatosplenomegaly and renal enlargement improved.
worsened (D–F).blood cell count and serum levels of liver enzymes, blood
urea nitrogen and creatinine (Cr) were within normal range.
Urinalysis showed mild proteinuria of 0.4 mg/mg ∙ Cr
without hematuria. Enhanced whole body computed
tomography demonstrated systemic lymphadenopathy,
hepatosplenomegaly, renal enlargement and anasarca
(Figure 1A–C).
Bone marrow biopsy revealed a hyperplastic marrow
with megakaryocytic hyperplasia (Figure 2A) and mild
reticulin fibrosis (Figure 2B). An 18-fluoro-deoxyglucose
(FDG) positron emission tomography scan showed weak
FDG uptake by the bilateral cervical and inguinal lymph
nodes and spleen. Biopsies of the lymph nodes showed
scattered lymphoid follicles with atrophic germinal centers
and enlarged follicular dendritic cells, with surrounding
concentric rings of small lymphocytes and penetratingD
F
E
hepatosplenomegaly (B). Multiple lymph node enlargements were
(arrows in white) (C). After two weekly TCZ infusions, systemic




Figure 2 Histopathological findings of the bone marrow (A, B) and lymph nodes (C–E). (A) Hematoxylin and Eosin stain × 200. Bone
marrow biopsy showed hypercellular marrow with increased numbers of megakaryocytes, including micro- and multi-separated nuclear
megakaryocytes and megaloblastic change. (B) Silver stain × 200. Silver stain showed mild reticulin fibrosis. (C) Hematoxylin and Eosin
stain × 200. A high-power field in the lymph node showed scattered lymphoid follicles with atrophic germinal centers, enlarged follicular
dendritic cells, surrounding concentric rings of small lymphocytes, and penetrating vessels. (D) Hematoxylin and Eosin stain × 200. The
interfollicular area was characterized by the proliferation of highly dense endothelial vessels and moderate numbers of mature plasma cells.
(E) CD21 immunostain × 200. Immunostaining for CD21 showed tight/concentric and expanded/disrupted pattern of follicular dendritic
cells. These findings were compatible with mixed-type Castleman’s disease.
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licular area was characterized by prominent vascularity
and moderate numbers of mature plasma cells (Figure 2D).
Immunological studies showed decreased numbers of
B-cells and CD57+ T-cells in the germinal centers. Im-
munostaining for CD21 demonstrated tight/concentric
and expanded/disrupted patterns of follicular dendritic
cells (Figure 2E). These findings were compatible with
the mixed type of Castleman’s disease.
Autoantibodies, serum M-protein and urine Bence-Jones
protein were not detected in this patient. Blood culture
and quantitative PCR examinations for cytomegalovirus,
Epstein-Barr virus, human herpes virus type 8 (HHV-8)
and human immunodeficiency virus (HIV) were all nega-
tive. There were no significant pathological findings of
malignancy in lymph node or liver biopsies.
Despite treatment with antibiotics and albumin, the
disease progressed markedly to respiratory distress, oli-
guric renal failure, anemia and thrombocytopenia. Meth-
ylprednisolone pulse therapy at a dose of 1000 mg/day for
3 consecutive days was initiated on day 10 after admission,
but the patient’s fever persisted and his CRP remained ele-
vated. The patient was diagnosed with multicentricCastleman’s disease and treatment was initiated with
weekly TCZ at a dose of 8 mg/kg, high dose intravenous
immunoglobulin and 80 mg of prednisolone (PSL) daily.
Weekly TCZ dramatically improved the patient’s symp-
toms and laboratory findings. However, anasarca persisted
(Figure 1D–F). With removal of ascites, anasarca gradually
disappeared.
One month after the initiation of TCZ therapy, the
patient was forced to decrease his PSL dose because of
steroid psychosis. In addition, he developed blisters over
his entire body and was forced to discontinue treatment
with TCZ because drug reaction or viral infection was
suspected. Paraneoplastic pemphigus and pemphigoid,
which are reported complications of Castleman’s disease
[7-9], were ruled out by negative antibody and immuno-
fluorescence testing. We diagnosed the patient’s skin le-
sions as toxic epidermal necrolysis by pathology, but were
unable to determine the cause.
After treatment for multicentric Castleman’s disease
was discontinued, the patient’s clinical symptoms reap-
peared with elevated cytokine levels. Restarting weekly
TCZ resulted in improvement in these findings (Figure 3).



































































































Figure 3 Patient’s clinical course. A: Cytokine profiles; B: Clinical symptoms and complications; C: Treatment; D: Laboratory data. IL-6:
interleukin-6; IVIG: intravenous injection of immunoglobulin (⇩); mPSL: methylprednisolone; PSL: prednisolone; sTNF-R: soluble tumor necrosis
factor receptor; TCZ: tocilizumab (↓); TEN: toxic epidermal necrolysis; VEGF: vascular endothelial cell growth factor.
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admission, the patient was discharged. One year after dis-
ease onset, the patient continued treatment with 5 mg
PSL daily and TCZ every 3 weeks without any signs of re-
currence. His clinical symptoms completely matched
those of TAFRO syndrome.Cytokine profile of serum, plasma and ascites
In the acute phase of the disease, the patient’s serum
cytokine levels of IL-6, IL-7, IL-10, IL-12p70, IL-15, IL-16,
soluble tumor necrosis factor receptors I and II (sTNF-R
I/II), VEGF, neopterin, interferon gamma-induced protein
10 (IP-10), macrophage inflammatory protein 1β (MIP-1β),
eotaxin-3 and monocyte chemoattractant protein 1 (MCP-1)
were elevated (Table 1). After initiation of TCZ therapy,
serum IL-6 levels increased because of IL-6 receptor
blocking by TCZ (Figure 3). After repeated TCZ infusions,
most of the serum and plasma cytokine/chemokine levels
decreased, including IL-6. When TCZ therapy was discon-
tinued because of steroid psychosis and toxic epidermal
necrolysis, cytokine levels transiently increased. After
restarting TCZ therapy, cytokine levels decreased once
more (Figure 3).
Aspiration of ascites was performed twice with a total
volume of 11.2 L removed. IL-6 and VEGF levels in the
ascitic fluid were extremely high (Table 1).Cytokine and chemokine determination
Serum and plasma concentrations of IL-6, IL-18, tumor
necrosis factor α (TNF-α), sTNF-R I/II, VEGF and
neopterin were determined by using the following
enzyme-linked immunosorbent assay (ELISA) kits: neop-
terin (IBL, Hamburg, Germany); IL-6, TNF-α, sTNF-R I/II
and VEGF (R&D Systems Inc., Minneapolis, MN, USA);
and IL-18 (MBL, Nagoya, Japan). Other cytokines/chemo-
kines were determined by electrochemiluminescence im-
munoassay (MSD, Rockville, MD, USA).Discussion
Multicentric Castleman’s disease is thought to comprise
several disease entities, including idiopathic and sec-
ondary multicentric Castleman’s disease in conditions
such as POEMS syndrome, autoimmune disease-associated
lymphadenopathy and malignant lymphoma [10,11]. In
contrast to its prevalence in Western countries [11,12],
multicentric Castleman’s disease associated with HIV and/
or HHV-8 is uncommon in Japan, where the disease usually
demonstrates a relatively chronic course. Kojima et al.
classified Japanese multicentric Castleman’s disease into
two subtypes on the basis of clinicopathological findings:
(1) idiopathic plasmacytic lymphadenopathy with poly-
clonal hyperimmunoglobulinemia (IPL type) and (2)
non-IPL type, which is atypical multicentric Castleman’s
Table 1 Cytokine profiles of serum, plasma and ascites
Serum Ascites Reference range
On admission Day 17 (before weekly TCZ) Day 321 Day 29 Day 36 Serum
IL-1α pg/mL <1.37 <1.37 <1.37 <1.37 <1.37 0.29–62.1
IL-1β pg/mL <0.640 <0.640 <0.640 1.620 0.826 0.11–24.3
IL-2 pg/mL <1.78 <1.78 <1.78 6.84 2.00 0.22–2.68
IL-4 pg/mL 0.542 0.376 0.642 2.90 3.84 N.A.
IL-5 pg/mL <3.2 <3.2 <3.2 6.70 5.72 0.11–0.62
IL-6 pg/mL 29 5.0 5.0 4400 4700 <3
IL-7 pg/mL 146 54.6 89.0 17.6 20.8 0.37–2.78
IL-8 pg/mL 230 348 34.8 >798 522 1.48–1720
IL-10 pg/mL 3.28 23.2 1.36 8.00 10.4 0.06–3.08
IL-12p70 pg/mL 3.40 3.16 3.20 5.30 31.0 0.26–0.38
IL-12/IL-23p40 pg/mL 488 49.2 330 45.2 93.6 13.1–159
IL-13 pg/mL 6.98 8.28 8.90 17.0 12.0 0.60–2.78
IL-15 pg/mL 11.6 36.8 4.74 34.8 43.6 0.56–3.01
IL-16 pg/mL 1054 1266 628 366 610 24–137
IL-17A pg/mL <17.7 <17.7 <17.7 <17.7 <17.7 0.28–4.87
IL-18 pg/mL 360 230 182 75.0 80.0 <500
IFN-γ pg/mL 14.8 <5.12 22.2 19.3 10.7 0.64–14.4
TNF-α pg/mL <5 <5 N.D. <5 <5 <5
sTNF-RI pg/mL 7300 10200 1230 8000 4800 484–1407
sTNF-RII pg/mL 9600 21800 3450 6000 4200 829–2262
VEGF pg/mL N.D. 178* 16.4* 1860 1210 <38.3*
Neopterin nmol/L 10.0 28.5 4.00 16.7 15.5 <5
GM-CSF pg/mL <3.8 <3.8 <3.8 <3.8 <3.8 0.18–0.18
IP-10 pg/mL >2000 >2000 928 1200 1440 28.5–237
MIP-1α pg/mL 87.6 56.0 <55.2 71.6 77.2 12–202
MIP-1β pg/mL 628 480 452 166 188 7.29–95.2
Eotaxin pg/mL 76.8 <48.8 228 85.6 162 19.0–145
Eotaxin-3 pg/mL 61.2 68.0 76.0 404 624 7.63–8.73
TARC pg/mL 132 58.8 860 30.2 33.2 5.39–70.0
MCP-1 pg/mL >1508 528 632 >1508 >1508 75.7–205
MCP-4 pg/mL 180 47.2 209 36.2 39.2 11.2–117
MDC pg/mL 1960 330 2740 <320 374 606–3249
IL: interleukin; IFN: interferon; TNF: tumor necrosis factor; sTNF-RI: soluble tumor necrosis factor receptor type I; sTNF-RII: soluble tumor necrosis factor receptor
type II; VEGF: vascular endothelial cell growth factor; GM-CSF: granulocyte macrophage colony-stimulating factor; IP-10: interferon gamma-induced protein 10;
MIP: macrophage inflammatory protein; TARC: thymus and activation regulated chemokine; MCP: monocyte chemoattractant protein; MDC: macrophage-derived
chemokine; N.A: not available; N.D: not determined: *: values derived from plasma.
Kubokawa et al. BMC Pediatrics 2014, 14:139 Page 5 of 8
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type histology and a high incidence of massive effusion
and autoimmune disease [13]. IPL is considered a homo-
geneous disease entity, whereas non-IPL type is a hetero-
geneous cluster of disease entities [13,14].
Recently Takai et al. reported three cases that shared a
constellation of clinical symptoms: thrombocytopenia,
anasarca, fever, reticulin fibrosis of the bone marrow and
organomegaly. These symptoms were tentatively given theclinical name “TAFRO syndrome” to describe the new dis-
ease concept [6]. In 2013, Japanese national meetings were
held to define TAFRO syndrome more clearly as a systemic
inflammatory disease characterized by a constellation of
symptoms: thrombocytopenia, anasarca, reticulin fibrosis of
the bone marrow, renal dysfunction and organomegaly [1].
Other clinical findings include anemia, immunologic dis-
order and rarely polyclonal hyper-γ-globulinemia [1]. As a
subtype of non-IPL, TAFRO syndrome is characterized
Table 2 Clinical features of TAFRO syndrome in eight previously reported cases and in our case




















1 47/F 1.5 + + No data + 10.9 1046 No data 285 (<115) No data CHOP, PSL Survival [6]
2 56/M 1.9 + + + + 10.7 863 7.2 (<4) 31 (<115) No data PSL, IVIG,
CyA
Survival




4 49/F 1.7 + + + + 6.2 2611 11 (No data) 330 (No data) unclear DEX,
PSL, CyA
Survival [2]
























CD: Castleman’s disease; CHOEP: cyclophosphamide, doxorubicin, vincristine, etoposide and prednisolone; CHOP: cyclophosphamide, doxorubicin, vincristine and prednisolone; CyA: cyclosporine A; Hb: hemoglobin; HV:
hyaline vascular type; IgG: immunoglobulin G; IL-6: interleukin-6; IVIG: intravenous immunoglobulin; MOF: multiple organ failure; mPSL: methylprednisolone; PC: plasma cell type; PLT: platelet; PSL: prednisolone; RTX:
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http://www.biomedcentral.com/1471-2431/14/139histologically as mostly a mixed type of Castleman’s dis-
ease, with an abnormal follicular dendritic cell network
[1]. TAFRO syndrome is considered a novel clinical entity
belonging to systemic inflammatory disorders and fea-
turing immunological abnormality beyond the ordinary
spectrum of multicentric Castleman’s disease [1].
It is thought that the pathogenesis of TAFRO syndrome
might be associated with a strong hypercytokine storm,
including IL-6 and VEGF [1,5]. In our patient, serum and
plasma levels of not only IL-6 and VEGF but also of other
cytokines/chemokines were markedly elevated (Table 1). It
is not clear how these cytokines/chemokines are associ-
ated with this disease. Further studies are needed to clarify
the roles of these cytokines/chemokines. It is interesting
that the levels of IL-6 and VEGF in the ascitic fluid of our
patient were markedly higher than the levels in his serum
and plasma. One previous case has been reported of a pa-
tient with severe anasarca and markedly elevated IL-6,
suggesting systemic inflammation of the serosa [3].
It is thought that the thrombocytopenia seen in TAFRO
syndrome might be caused by an immune-mediated
mechanism and can be overcome by anti-inflammatory
therapy [2-4]. The mechanism of renal failure in pa-
tients with TAFRO syndrome is not clear because histo-
logical examinations of kidneys have not been reported
in this disease. Previous studies have reported that patients
with Castleman’s disease manifest renal symptoms such as
nephrotic syndrome and acute renal failure and that
histologic findings were heterogeneous, including vari-
ous glomerular lesions, thrombotic microangiopathy-like
lesions, interstitial nephritis and amyloidosis [15,16]. In
our case, urinalysis showed mild proteinuria and mildly
elevated urinary N-acetyl-beta-D-glucosaminidase and β2-
microglobulin without fractural red blood cells in periph-
eral blood before the onset of renal failure. These findings
suggest that the kidney pathophysiology in this case was
interstitial nephritis rather than glomerular nephritis,
thrombotic microangiopathy or amyloidosis.
Eight cases of TAFRO syndrome have previously been
reported [2-6]. All cases including ours are summarized in
Table 2. This disease generally occurs in the middle-aged
and elderly [1-6]. There are no adolescent cases reported
to date, and this is the first case of a young patient with an
apparent diagnosis of TAFRO syndrome. All patients were
treated with steroids and some improved with the addition
of cyclosporine A [2,6] or TCZ [3,4] with rituximab ther-
apy [3]. Unfortunately, three of the eight patients died
[5,6], indicating that this syndrome sometimes results in a
fatal outcome in spite of treatment.
There are no reports of TAFRO syndrome outside of
Japan. However, we found one report of multicentric
Castleman’s disease in a 4-year-old Hispanic girl with
thrombocytopenia, anasarca and renal failure [17]. Although
the authors diagnosed the patient with multicentricCastleman’s disease and did not comment on reticulin
fibrosis of the bone marrow, her clinical characteristics
were quite similar to those of our patient and to other
cases of TAFRO syndrome. The question remains whether
TAFRO syndrome should be classified as a distinct disease
entity rather than as an atypical subtype of multicentric
Castleman’s disease. All of the features of TAFRO
syndrome can be seen in severe flares of multicentric
Castleman’s disease. For example, anasarca and organo-
megaly are common [11], and thrombocytopenia and
renal dysfunction are frequently reported in Castleman’s
disease [10,14-17]. In contrast, reticulin fibrosis of the
bone marrow occurs less frequently, but it is not specific
for TAFRO syndrome or for multicentric Castleman’s dis-
ease. Establishing TAFRO syndrome as an independent
disease entity remains controversial. Further investigation
with clinical and pathological studies is necessary to estab-
lish TAFRO syndrome as a new syndromic disease.
Conclusions
It is important to note that TAFRO syndrome occurs
not only in adults, but also in adolescents. In the acute
phase, TAFRO syndrome should be treated with rapid
and strong immunosuppressive therapy including TCZ
to prevent a fatal outcome. We believe that cytokine
profiling is useful not only to assess the pathogenesis
but also to monitor disease activity of this rare disease.
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